Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet Lond Engl. 2006;367(9516):1066–74.
Collier ARY, Molina RL. Maternal mortality in the United States: updates on trends, causes, and solutions. NeoReviews. 2019;20(10):e561–74.
Article PubMed PubMed Central Google Scholar
Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243–62.
Heemelaar S, Petrus A, Knight M, van den Akker T. Maternal mortality due to cardiac disease in low- and middle-income countries. Trop Med Int Health. 2020;25(6):673–86.
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Kardiol Pol. 2019;77(3):245–326.
Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol. 2010;116(6):1302–9.
Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–78.
Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(2):207–21.
Article CAS PubMed Google Scholar
McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905–14.
Reza N, Packard E, Goli R, Chowns JL, Owens AT, Arany Z, et al. Clinical predictors of referral for and yield of genetic testing in peripartum cardiomyopathy. JACC Heart Fail. 2023;11(9):1278–80.
Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121(13):1465–73.
Article CAS PubMed Google Scholar
Haghikia A, Podewski E, Libhaber E, Labidi S, Fischer D, Roentgen P, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013;108(4):366.
Article CAS PubMed PubMed Central Google Scholar
Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38(35):2671–9.
Article CAS PubMed PubMed Central Google Scholar
Writing Committee Members, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-327.
Lewey J, Haythe J. Cardiomyopathy in pregnancy. Semin Perinatol. 2014;38(5):309–17.
Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol. 2009;55(1):45–52.
Stergiopoulos K, Shiang E, Bench T. Pregnancy in patients with pre-existing cardiomyopathies. J Am Coll Cardiol. 2011;58(4):337–50.
Lloji A, Panza JA. The challenge of pregnancy in women with hypertrophic cardiomyopathy. Cardiol Rev. 2022;30(5):258–62.
Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40(10):1864–9.
Moolla M, Mathew A, John K, Yogasundaram H, Alhumaid W, Campbell S, et al. Outcomes of pregnancy in women with hypertrophic cardiomyopathy: a systematic review. Int J Cardiol. 2022;15(359):54–60.
Canobbio MM, Warnes CA, Aboulhosn J, Connolly HM, Khanna A, Koos BJ, et al. Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2017;135(8):e50-87.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-1032.
Hameed AB, Chan K, Ghamsary M, Elkayam U. Longitudinal changes in the B-type natriuretic peptide levels in normal pregnancy and postpartum. Clin Cardiol. 2009;32(8):E60-62.
Article PubMed PubMed Central Google Scholar
Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol. 2010;56(15):1247–53.
Article CAS PubMed Google Scholar
Resnik JL, Hong C, Resnik R, Kazanegra R, Beede J, Bhalla V, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol. 2005;193(2):450–4.
Article CAS PubMed Google Scholar
Kampman MAM, Balci A, van Veldhuisen DJ, van Dijk APJ, Roos-Hesselink JW, Sollie-Szarynska KM, et al. N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease. Eur Heart J. 2014;35(11):708–15.
Article CAS PubMed Google Scholar
Chang SA, Khakh P, Janzen M, Lee T, Kiess M, Rychel V, et al. Trending cardiac biomarkers during pregnancy in women with cardiovascular disease. Circ Heart Fail. 2022;15(8): e009018.
Article CAS PubMed Google Scholar
Clerico A, Zaninotto M, Aimo A, Cardinale DM, Dittadi R, Sandri MT, et al. Variability of cardiac troponin levels in normal subjects and in patients with cardiovascular diseases: analytical considerations and clinical relevance. Clin Chem Lab Med. 2023;61(7):1209–29.
Article CAS PubMed Google Scholar
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618–51.
Dockree S, Brook J, Shine B, James T, Green L, Vatish M. Cardiac-specific troponins in uncomplicated pregnancy and pre-eclampsia: A systematic review. PLoS ONE. 2021;16(2): e0247946.
Article CAS PubMed PubMed Central Google Scholar
Furenäs E, Eriksson P, Wennerholm UB, Dellborg M. Pregnancy in a healthy population: dynamics of NTproBNP and hs-cTroponin T. Open Heart. 2020;7(2): e001293.
Article PubMed PubMed Central Google Scholar
Perrone MA, Zaninotto M, Masotti S, Musetti V, Padoan A, Prontera C, et al. The combined measurement of high-sensitivity cardiac troponins and natriuretic peptides: a useful tool for clinicians? J Cardiovasc Med (Hagerstown). 2020;21(12):953–63.
Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33(16):2001–6.
Article CAS PubMed Google Scholar
Silversides CK, Grewal J, Mason J, Sermer M, Kiess M, Rychel V, et al. Pregnancy outcomes in women with heart disease: the CARPREG II study. J Am Coll Cardiol. 2018;71(21):2419–30.
Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001;104(5):515–21.
Article CAS PubMed Google Scholar
Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart Br Card Soc. 2006;92(10):1520–5.
van Hagen IM, Boersma E, Johnson MR, Thorne SA, Parsonage WA, Escribano Subías P, et al. Global cardiac risk assessment in the registry of pregnancy and cardiac disease: results of a registry from the European Society of Cardiology. Eur J Heart Fail. 2016;18(5):523–33.
Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJM, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010;31(17):2124–32.
DeFilippis EM, Haythe JH, Walsh MN, Kittleson MM. Intersection of heart failure and pregnancy: beyond peripartum cardiomyopathy. Circ Heart Fail. 2021;14(5): e008223.
Power to Decide. One Key Question online. Available from: https://powertodecide.org/one-key-question. Accessed 27 oct 2023.
Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, et al. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. Circulation. 2020;141(23):e884-903.
Cauldwell M, Ghonim S, Uebing A, Swan L, Steer PJ, Gatzoulis M, et al. Preconception counseling, predicting risk and outcomes in women with mWHO 3 and 4 heart disease. Int J Cardiol. 2017;1(234):76–80.
American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care. Gynecologic considerations for adolescents and young women with cardiac conditions: ACOG Committee Opinion, number 819. Obstet Gynecol. 136(5):e90–9.
Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin no. 206. Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133(2):e128–50.
DeFilippis EM, Bhagra C, Casale J, Ging P, Macera F, Punnoose L, et al. Cardio-obstetrics and heart failure: JACC: heart failure state-of-the-art review. JACC Heart Fail. 2023;11(9):1165–80.
Pieper PG. Use of medication for cardiovascular disease during pregnancy. Nat Rev Cardiol. 2015;12(12):718–29.
留言 (0)